Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Inventory (2022 - 2025)

Historic Inventory for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $23.8 million.

  • Axsome Therapeutics' Inventory rose 6665.97% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 6665.97%. This contributed to the annual value of $15.7 million for FY2024, which is 394.45% up from last year.
  • Per Axsome Therapeutics' latest filing, its Inventory stood at $23.8 million for Q3 2025, which was up 6665.97% from $18.4 million recorded in Q2 2025.
  • Axsome Therapeutics' Inventory's 5-year high stood at $23.8 million during Q3 2025, with a 5-year trough of $4.3 million in Q4 2022.
  • For the 4-year period, Axsome Therapeutics' Inventory averaged around $13.6 million, with its median value being $14.7 million (2023).
  • Data for Axsome Therapeutics' Inventory shows a peak YoY increase of 25034.72% (in 2023) and a maximum YoY decrease of 2861.79% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Inventory (Quarter) stood at $4.3 million in 2022, then skyrocketed by 250.35% to $15.1 million in 2023, then increased by 3.94% to $15.7 million in 2024, then surged by 51.12% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q3 2025, $18.4 million for Q2 2025, and $16.3 million during Q1 2025.